What is the pregnancy category of Olmesartan?

Olmesartan is classified as a pregnancy category D medication. This designation indicates that there is positive evidence of human fetal risk based on data from investigational or marketing experience or studies in humans, but the potential benefits of using the drug in a pregnant woman may outweigh the risks. Specifically, Olmesartan is an angiotensin II receptor blocker (ARB) that can cause injury or death to developing fetus, especially in the second and third trimesters, as it can lead to issues such as kidney dysfunction, low amniotic fluid levels, and pulmonary hypoplasia.

Understanding the risks associated with Olmesartan during pregnancy is crucial, as healthcare providers are typically advised to seek alternative antihypertensive therapies in pregnant patients to mitigate any potential adverse outcomes. This knowledge is essential for safely managing blood pressure in pregnant patients while considering the health of both the mother and the developing fetus.